Fundraising Fox
Transcode Therapeutics
NASDAQ: RNAZBoston, US · Delaware corporation
Find your way into Transcode Therapeutics
Sign up to see every warm intro you have to Transcode Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Transcode Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
TransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
Founders & leadership
TA
Thomas A. FitzgeraldExecutive
PP
Philippe P. CalaisCEO & Chairman, Transcode Therapeutics (NASDAQ: RNAZ)Philippe P. Calais is CEO and Chairman of TransCode Therapeutics. He brings over three decades of life sciences executive experience, including senior leadership roles at Hoffmann-La Roche, and a track record of leading public and private biotechnology companies through IPOs, financings, and M&A.
Board
MM
Magda MarquetBoard director
EM
Erik MantingBoard director
Reported raises · per SEC filings
Form D private placements$8M disclosed across 1 round · 2024
▶$8MraisedDec 2024 · 6 investors · BiotechnologyRule 506(b)
▶$8MraisedDec 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Magda MarquetDirector
- Erik MantingDirector
- Thomas A. FitzgeraldExecutive Officer, Director
- Philippe CalaisDirector
- Offering amount
- $8M
- Amount sold
- $8M
- Sales commissions
- $320K
- Placement agents
- The Benchmark Company LLC, A.G.P./Alliance Global Partners
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Day One BiopharmaceuticalsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Companies working in the same space as Transcode Therapeutics.
Frequently asked questions
- What does Transcode Therapeutics do?
- TransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
- Who founded Transcode Therapeutics?
- Transcode Therapeutics was founded by Zdravka Medarova, Anna Moore.
- How much funding has Transcode Therapeutics raised?
- Transcode Therapeutics has disclosed $8M raised across 1 round.
- Where is Transcode Therapeutics headquartered?
- Transcode Therapeutics is headquartered in Boston, US.